We bring you the latest news from the healthcare about the health care in the United Kingdom.

zaterdag 24 februari 2018

The Lancet: [Articles] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, d...

[Articles] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
The primary endpoint of disease-free survival was not met in cohort 2, and therefore the analysis of cohort 1 showing a numerical benefit in disease-free survival with vemurafenib versus placebo in patients with resected stage IIC�CIIIA�CIIIB BRAFV600 mutation-positive melanoma must be considered exploratory only. 1 year of adjuvant vemurafenib was well tolerated, but might not be an optimal treatment regimen in this patient population.
Read more

[Comment] The brim of uncertainty in adjuvant treatment of melanoma
Until recently, standard options for adjuvant melanoma therapy have been limited to interferon-α and ipilimumab, both of which are associated with substantial toxicity and only modest clinical benefit.1�C3 2017 was a major year for the adjuvant treatment of melanoma as two new regimens were shown to significantly lower the risk of recurrence in patients with resected, high-risk melanoma. The anti-programmed death 1 agent, nivolumab (compared with ipilimumab in the Checkmate 238 study4) and the combination of the RAF and MEK inhibitors, dabrafenib and trametinib (compared with placebo in the COMBI-AD study5) were both shown to improve disease-free survival.
Read more

[News] Possible X chromosome-linked transmission of ovarian cancer
A family history of ovarian cancer is the most reliable predictor of a woman developing the disease, but current genetic models do not explain why the sisters of a woman diagnosed with ovarian cancer have a higher risk of developing the disease than their mother. Findings from a new study suggest an X chromosome-linked pattern of inheritance for ovarian cancer from fathers to daughters.
Read more

[News] Ultra-processed foods might increase cancer risk
The consumption of ultra-processed foods might be proportionally linked to an increased cancer risk, according to results from the ongoing NutriNet-Santé cohort study.
Read more

[Comment] Adjuvant aromatase inhibition: more options for patients
Aromatase inhibitors are the preferred treatment for postmenopausal patients with hormone receptor-positive early breast cancer.1 Third-generation aromatase inhibitors exist in two classes with different modes of action: reversible binding of the aromatase enzyme by the non-steroidal aromatase inhibitors anastrazole and letrozole, and irreversible inhibition of the enzyme by the steroidal aromatase inhibitor exemestane.
Read more